Finch Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Finch Therapeutics's estimated annual revenue is currently $19.5M per year.
- Finch Therapeutics received $36.0M in venture funding in March 2018.
- Finch Therapeutics's estimated revenue per employee is $697,500
- Finch Therapeutics's total funding is $188.8M.
- Finch Therapeutics's current valuation is $432.1M. (January 2022)
Employee Data
- Finch Therapeutics has 28 Employees.
- Finch Therapeutics grew their employee count by -49% last year.
Finch Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Translational Medicine | Reveal Email/Phone |
3 | SVP Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
4 | SVP | Reveal Email/Phone |
5 | Associate Director Process Development | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Senior Director and Head Manufacturing | Reveal Email/Phone |
8 | Director Program Management | Reveal Email/Phone |
9 | Director GMP Quality Assurance | Reveal Email/Phone |
10 | Director Manufacturing Operations (Feb 2023) | Reveal Email/Phone |
Finch Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Finch Therapeutics?
Finch Therapeutics is unlocking the therapeutic potential of the microbiome through our human-first discovery platform. We use machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus our in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patients lives.
keywords:Pharmaceuticals
$188.8M
Total Funding
28
Number of Employees
$19.5M
Revenue (est)
-49%
Employee Growth %
$432.1M
Valuation
N/A
Accelerator
Finch Therapeutics News
The workforce reduction, which will impact 37 employees, follows Finch's recent move to pause its chronic hepatitis B program, the clinical hold...
Finch Therapeutics reported Tuesday morning that it would be laying off 37 staffers, or approximately 20% of its workforce,...
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class...
Clinical-stage microbiome drug development company Finch Therapeutics announced that it has raised a $90 million Series D funding round Clinical-stage microbiome drug development company Finch Therapeutics announced that it has raised a $90 million Series D funding round. New investors in this ...
Other Companies in Somerville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 28 | 180% | N/A |
#2 | $2.8M | 28 | 40% | N/A |
#3 | $5.7M | 28 | 0% | N/A |
#4 | $5.7M | 28 | -24% | N/A |
#5 | N/A | 28 | 8% | N/A |
Finch Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-03-02 | $36.0M | B | Multiple | Article |